Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 301–400 of 1,004
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Kronenberg, F., Mora, S., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000855 · Cited by 78
Familial Hypercholesterolemia: An Under‐recognized but Significant Concern in Cardiology Practice
Foody, J. M. (2013) · Clinical Cardiology · doi:10.1002/clc.22223 · Cited by 76
Early identification of cardiovascular risk using genomics and proteomics
Kullo, I. J., & Cooper, L. T. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.53 · Cited by 82
“Similarly, variants in LPA that are associated with higher levels of lipoprotein(a) are in turn associated with an increased risk of CHD”
BackgroundCairns, B. J., Coffey, S., Travis, R. C., Prendergast, B., Green, J., Engert, J. C., Lathrop, M. G., Thanassoulis, G., & Clarke, R. (2017) · Circulation · doi:10.1161/circulationaha.116.026103 · Cited by 82
Self-citationYoon, Y., Ahn, J., Kang, D., Lee, P. H., Kang, S., Park, D., Lee, S., Kim, Y., Han, K. H., Lee, C. W., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.07.042 · Cited by 74
“Previous large epidemiologic and genetic studies based on the general population without established coronary artery disease had shown that Lp(a) levels are genetically determined and could be a causal factor for the development of atherosclerotic cardiovascular disease (15,17-19).”
BackgroundLow lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1085 · Cited by 72
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 76
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 75
Predicting Stroke Through Genetic Risk Functions: The CHARGE Risk Score Project
Ibrahim‐Verbaas, C. A., Fornage, M., Bis, J. C., Choi, S. H., Psaty, B. M., Meigs, J. B., Rao, M., Nalls, M. A., Fontes, J. D., O’Donnell, C. J., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.003044 · Cited by 77
Shapiro, M. D., Minnier, J., Tavori, H., Kassahun, H., Flower, A., Somaratne, R., & Fazio, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010932 · Cited by 70
Genetics of coronary artery disease: Genome-wide association studies and beyond
Prins, B. P., Lagou, V., Asselbergs, F. W., Snieder, H., & Fu, J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.015 · Cited by 74
“orf105 [21] F21 [20] C22A3, LPAL2, LPA Lp(a) level [20] [19] TK1 [26] CAP29 [25] 3HC1 [20] DKN2A, CDKN2 Abdominal aortic aneurysm, intracranial aneurysm [10,12,14-16, 20,25,27] TAP Type 2 diabetes [27] BO Serum phytosterol level, plasma levels of liver enzymes, venous thromboembolism, E-selectin levels, adhesion level…”
BackgroundMethodThe Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 79
Ray, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.896 · Cited by 69
McGurk, K. A., Keavney, B. D., & Nicolaou, A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.021 · Cited by 79
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, Hooper, & Watts (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 64
Bajaj, A., Damrauer, S. M., Anderson, A. H., Xie, D., Budoff, M. J., Go, A. S., He, J., Lash, J. P., OJO, A. O., Post, W. S., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309920 · Cited by 69
Chen, H. Y., Dufresne, L., Burr, H., Ambikkumar, A., Yasui, N., Luk, K., Ranatunga, D. K., Whitmer, R. A., Lathrop, M., Engert, J. C., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4266 · Cited by 64
Self-citationYe, J., Zhuang, X., Li, X., Gong, X., Sun, Y., Wang, W., Feng, S., Wu, T., & Zhong, B. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155294 · Cited by 70
Bhatia, H. S., & Wilkinson, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206040 · Cited by 72
“[2] 2009 LPA locus had strongest association with coronary disease in large study of candidate SNPs LPA SNP rs10455872 OR 1.”
BackgroundPuzzling role of genetic risk factors in human longevity: “risk alleles” as pro-longevity variants
Ukraintseva, S., Yashin, A., Arbeev, K., Kulminski, A., Akushevich, I., Wu, D., Joshi, G., Land, K. C., & Stallard, E. (2016) · Biogerontology · doi:10.1007/s10522-015-9600-1 · Cited by 67
“Several LPA [lipoprotein, Lp(a)] genotypes, which result in elevated Lp(a) levels, were shown to increase the risk of CVD (Clarke et al. 2009).”
BackgroundMendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 68
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
Arai, K., Orsoni, A., Mallat, Z., Tedgui, A., Witztum, J. L., Bruckert, E., Tselepis, A. D., Chapman, M. J., & Tsimikas, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p027235 · Cited by 67
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice
Chennamsetty, I., Kostner, K. M., Claudel, T., Vinod, M., Frank, S., Weiss, T. S., Trauner, M., & Kostner, G. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m029769 · Cited by 66
Lipoprotein(a)-cholesterol: A significant component of serum cholesterol
Kinpara, K., Okada, H., Yoneyama, A., Okubo, M., & Murase, T. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.05.036 · Cited by 67
Genetic Variants in the Apolipoprotein(a) Gene and Coronary Heart Disease
Li, Y., Luke, M. M., Shiffman, D., & Devlin, J. J. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959601 · Cited by 70
“33 In prospective studies, rs3798220 was associated (1) with incident MI among 3849 Caucasian men and women age 65 years or older in the Cardiovascular Health Study (CHS),36 (2) with incident major cardiovascular events (including MI, ischemic stroke, and cardiovascular death) among 25 131 initially healthy women age…”
BackgroundMethodSerban, M.-C., Sahebkar, A., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Muntner, P., Blaha, M. J., Andrica, F., Martin, S. S., Borza, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19188 · Cited by 64
“Eligible studies were reviewed and the following data were abstracted: (1) first author’s name, (2) year of publication, (3) study location; (4) study design; (5) number of participants in the L-carnitine and control (in case of randomized design) groups, (6) age, gender and body mass index (BMI) of study participants…”
MethodMarcovina, S. M., Viney, N. J., Hughes, S. G., Xia, S., Witztum, J. L., & Tsimikas, S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.024 · Cited by 69
Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target
Fusco, S. A. D., Arca, M., Scicchitano, P., Alonzo, A., Perone, F., Gulizia, M. M., Gabrielli, D., Oliva, F. G., Imperoli, G., & Colivicchi, F. (2022) · Heart · doi:10.1136/heartjnl-2021-320708 · Cited by 71
Amiri, M., Raeisi‐Dehkordi, H., Verkaar, A. J. C. F., WU, Y., van Westing, A. C., Berk, K. A., Bramer, W. M., Aune, D., & Voortman, T. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-022-00956-4 · Cited by 70
“In addition, large genetic and epidemiological studies have indicated that higher levels of Lp(a) is a causal risk factor for myocardial infarction [2], coronary disease [4], atherosclerosis stenosis [88], aorticvalve calcification and aortic valve stenosis [3, 5, 89], which some mechanisms related to these diseases m…”
BackgroundAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Gutstein, D. E., Krishna, R., Johns, D. G., Surks, H. K., Dansky, H. M., Shah, S., Mitchel, Y., Arena, J. P., & Wagner, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.271 · Cited by 76
Han, X., Ong, J., Hewitt, A. W., Gharahkhani, P., & MacGregor, S. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa178 · Cited by 77
“Serum Lp(a) levels are mainly genetically determined by genetic variations in the LPA gene region, 56,57 none of which showed association with AMD risk.”
BackgroundCroyal, M., Ouguerram, K., Passard, M., Ferchaud-Roucher, V., Chétiveaux, M., Billon-Crossouard, S., de Gouville, A.-C., Lambert, G., Krempf, M., & Nobécourt, E. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305835 · Cited by 62
Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk
Tsimikas, S. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000237 · Cited by 62
“These findings are further supported by additional epidemiological as well as Mendelian randomization [4,5] and genome-wide association studies [6].”
BackgroundResultThe genetics of coronary heart disease
Swerdlow, D. I., Holmes, M. V., Harrison, S. C., & Humphries, S. E. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds009 · Cited by 66
Emerging therapeutic agents to lower lipoprotein (a) levels
Kolski, B., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 63
Blom, D. J., Koren, M. J., Roth, E., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12788 · Cited by 64
“Mendelian randomisation studies show the Lp(a) is an independent risk factor for atherosclerosis, although there is as yet no cardiovascular outcome evidence for Lp(a) lowering with drug therapy (33-35).”
BackgroundAntisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 59
“Epidemiologic studies showed a connection between elevated levels of Lp(a) and the risk of CVD [57,58], including myocardial infarction [59], coronary disease [60], aortic valve stenosis [61,62], and stroke [63].”
BackgroundNew and Emerging Risk Factors for Coronary Heart Disease
Akhabue, E., Thiboutot, J. P., Cheng, J.-W., Lerakis, S., Vittorio, T. J., Christodoulidis, G., Grady, K. M., & Kosmas, C. E. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aab45 · Cited by 71
Li, Z., Li, X., Liu, Y., Shen, J., Chen, H., Zhou, H., Morrison, A. C., Boerwinkle, E., & Lin, X. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.03.002 · Cited by 67
Genetic susceptibility, plant-based dietary patterns, and risk of cardiovascular disease
Heianza, Y., Zhou, T., Sun, D., Hu, F. B., Manson, J. E., & Qi, L. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa107 · Cited by 66
Nordestgaard, B. G., & Tybjærg-Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 67
van Dam-Nolen, D. H. K., van Dijk, A. C., Crombag, G. A. J. C., Lucci, C., Kooi, M. E., Hendrikse, J., Nederkoorn, P. J., Daemen, M. J. A. P., van der Steen, A. F. W., Koudstaal, P. J., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.004 · Cited by 63
Levin, M. G., Zuber, V., Walker, V. M., Klarin, D., Lynch, J., Malik, R., Aday, A. W., Bottolo, L., Pradhan, A. D., Dichgans, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053797 · Cited by 65
“Finally, as prior studies have identified an association between genetically-predicted Lp(a) and CAD, 28,31 we investigated the relationship between circulating Lp(a) and PAD risk.”
Abdul‐Rahman, T., Lizano-Jubert, I., Garg, N., Talukder, S., López, P. P., Awuah, W. A., Shah, R. M., Chambergo, D., Cantu‐Herrera, E., Farooqi, M., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.06.002 · Cited by 66
Lipoprotein(a): from Causality to Treatment
Kronenberg, F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01187-6 · Cited by 64
“Clarke and colleagues introduced for the first time the two SNPs, rs10455872 and rs3798220, and found that they were not only associated with high Lp(a) concentrations but also with a higher risk for coronary disease [24].”
BackgroundNovel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A., & Shaw, J. A. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 59
LDL as a Cause of Atherosclerosis
TOMKIN, G. H. (2012) · The Open Atherosclerosis & Thrombosis Journal · doi:10.2174/1876506801205010013 · Cited by 83
Kivimäki, M., Magnussen, C. G., Juonala, M., Kähönen, M., Kettunen, J., Loo, B.-M., Lehtimäki, T., Viikari, J., & Raitakari, O. T. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq205 · Cited by 61
Hopewell, J. C., Clarke, R., Parish, S., Armitage, J., Lathrop, M., Hager, J., & Collins, R. (2011) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.958371 · Cited by 60
“Confirmation of myocardial infarction required evidence of either (1) 2 or more of (a) typical symptoms, (b) diagnostic electrocardiographic changes, and (c) diagnostic elevations of cardiac enzyme concentrations or (2) necropsy findings of myocardial infarction that corresponded to symptom onset.”
BackgroundSelf-citationKyriakou, T., Seedorf, U., Goel, A., Hopewell, J. C., Clarke, R., Watkins, H., & Farrall, M. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303462 · Cited by 58
“hindering efficient secretion and resulting in lower circulating lipoprotein(a) levels.(5)”
BackgroundSelf-citationArsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 63
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
“found that elevated Lp(a) levels in FH were linked to a 2-fold higher prevalence of a specific single nucleotide polymorphism (rs10455872) on the LPA gene associated with an average 64 mg/dl increase in circulating Lp(a) levels (79) in that cohort compared with reference populations, suggesting that there may be an as…”
BackgroundWhat do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.004 · Cited by 61
“mg/dl, risk increased gradually with Lp(a) concentration from at least 30 mg/dL [21,24, 25].”
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 65
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Human genetics and its impact on cardiovascular disease
Tada, H., Fujino, N., Hayashi, K., Kawashiri, M., & Takamura, M. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.09.005 · Cited by 62
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 65
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
Tada, H., Takamura, M., & Kawashiri, M. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17034 · Cited by 60
Perrot, N., Thériault, S., Dina, C., Chen, H. Y., Boekholdt, S. M., Rigade, S., Després, A.-A., Poulin, A., Capoulade, R., Le Tourneau, T., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1581 · Cited by 52
Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations
Shah, N. P., Pajidipati, N. J., McGarrah, R. W., Návar, A. M., Vemulapalli, S., Blazing, M. A., Shah, S. H., Hernandez, A. F., & Patel, M. R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.043 · Cited by 65
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 62
“57 for two or more variants.(40) Mendelian randomization studies show a genetically de-”
BackgroundTherapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Stürzebecher, P. E., Schorr, J., Klebs, S. H. G., & Laufs, U. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.014 · Cited by 59
Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A. G., Chester Ridgway, E., & Ladenson, P. W. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12261 · Cited by 55
Burgess, S., & Harshfield, E. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000230 · Cited by 59
“This polymorphism (and also single nucleotide polymorphisms in the LPA region [34]) are also associated with CHD risk, suggesting a deleterious causal effect of increased lipoprotein(a) on CHD risk [33].”
BackgroundEvidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels
Lu, W., Cheng, Y.-C., Chen, K., Wang, H., Gerhard, G. S., Still, C. D., Chu, X., Yang, R., Parihar, A., O'Connell, J. R., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu731 · Cited by 52
“A previous study has shown similar results in that rare alleles of both rs10455872 and rs3798220 are each correlatedwith a smaller apolipoprotein(a) isoform (as assessed by immunoblotting) and a lower copy number (as assessed by quantitative PCR assay) (3).”
ResultAlexandros, D. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160009 · Cited by 61
Ellis, K. L., Pang, J., Chan, D. C., Hooper, A. J., Bell, D. A., Burnett, J. R., & Watts, G. F. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.011 · Cited by 60
Genetics of Coronary Artery Disease and Myocardial Infarction - 2013
Kessler, T., Erdmann, J., & Schunkert, H. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0368-0 · Cited by 61
“3 that markedly increases lipoprotein (a) levels and coronary disease risk by 51 % [28].”
BackgroundThe IL-33-ST2L Pathway Is Associated with Coronary Artery Disease in a Chinese Han Population
Tu, X., Nie, S., Liao, Y., Zhang, H., Fan, Q., Xu, C., Bai, Y., Wang, F., Ren, X., Tang, T., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.08.009 · Cited by 59
Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a)
Diffenderfer, M. R., Lamon-Fava, S., Marcovina, S. M., Barrett, P. H. R., Lel, J., Dolnikowski, G. G., Berglund, L., & Schaefer, E. J. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.031 · Cited by 51
“[18] Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al.”
Seventeen Years of Statin Pharmacogenetics: a Systematic Review
Leusink, M., Onland‐Moret, N. C., de Bakker, P. I. W., de Boer, A., & der Zee, A. H. M. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.158 · Cited by 62
Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns
Erhart, G., Lamina, C., Lehtimäki, T. J., Marques-Vidal, P. M., Kähönen, M. A. P., Vollenweider, P., Raitakari, O. T., Waeber, G., Thorand, B., Strauch, K., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310865 · Cited by 61
Arsenault, B. J., Pelletier, W., Kaiser, Y., Perrot, N., Couture, C., Khaw, K.-T., Wareham, N. J., Bossé, Y., Pibarot, P., Stroes, E. S. G., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0129 · Cited by 52
Advances in Genomics for Drug Development
Spreafico, R., Soriaga, L. B., Grosse, J., Virgin, H. W., & Telenti, A. (2020) · Genes · doi:10.3390/genes11080942 · Cited by 59
“In short, individuals with loss of function of these genes were protected from disease naturally while gain of function variants (PCSK9, NPC1L1, LPA) were associated with increased cardiovascular risk.”
BackgroundPantazi, D., Tellis, C. C., & Tselepis, A. D. (2022) · BioFactors · doi:10.1002/biof.1890 · Cited by 61
“Lp(a) is a genetic, causal, and independent risk factor for cardiovascular diseases.(5,6) OxPLs content may play an important role in Lp(a)-functionality.”
BackgroundSabater‐Lleal, M., Mälarstig, A., Folkersen, L., Artigas, M. S., Baldassarre, D., Kavousi, M., Almgren, P., Veglia, F., Brusselle, G., Hofman, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104082 · Cited by 58
“Association with CAD We also sought association in silico of the 26 lung function SNPs with CAD in 5,775 CAD cases and 7,265 controls using GWA data from the PROCARDIS [23] and Wellcome Trust Case Control Consortium (WTCCC) collections [24].”
InfluentialSelf-citationLipoprotein(a) mass: A massively misunderstood metric
McConnell, J. P., Guadagno, P. A., Dayspring, T. D., Hoefner, D. M., Thiselton, D. L., Warnick, G. R., & Harris, W. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.003 · Cited by 57
Impact of Genes and Environment on Obesity and Cardiovascular Disease
Heianza, Y., & Qi, L. (2018) · Endocrinology · doi:10.1210/en.2018-00591 · Cited by 58
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 57
Kronenberg, F. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00093-5 · Cited by 57
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 59
“…KIV repeats identified by pulsed-field gel electrophoresis or by the sum of KIV repeats of the two alleles by quantitative PCR or by the investigation of SNPs that are associated with high Lp(a) concentrations revealed the same finding (Clarke et al. 2009; Kamstrup et al. 2009; Kraft et al. 1996).”
Structural polymorphism and diversity of human segmental duplications
Jeong, H., Dishuck, P. C., Yoo, D., Harvey, W. T., Munson, K. M., Lewis, A. P., Kordosky, J., Garcia, G. H., Yilmaz, F., Hallast, P., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02051-8 · Cited by 61
“…SDs tend to occur in close proximity to previously known SDs (permutation test, empirical P 0.01), although we do note that certain chromosome arms and regions (for example, p-arms of chromosomes 8, 10, 16, 17 and 19 and q-arms of chromosomes 1, 15 and 22) show an excess of these rarer SDs (Fig.”
InfluentialAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 57
A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Cao, Y., Liu, H., Li, S., & Li, J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0303-2 · Cited by 55
Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead
Tsimikas, S. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319483 · Cited by 57
“11 In 2008 to 2011, proof of concept was demonstrated of the efficiency of antisense oligonucleotides in reducing plasma Lp(a).”
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
Clarke, R., Ende, A. V., Schmidt, L. E., Yin, X., Hill, M., Hughes, A. D., Pechlaner, R., Willeit, J., Kiechl, S. J., Watkins, H. C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321690 · Cited by 53
“spectrometry (MS) assay17 to include 13 apolipoproteins for the 4 main lipoproteins: (1) Lp(a)-related [Apo(a)-KR, Apo(a)-CR]; (2) LDL-related (ApoB); (3) triglyceriderelated (ApoC1, ApoC2, ApoC3, and ApoE); and (4) HDLrelated (ApoA1, ApoA2, ApoA4, ApoD, ApoH, ApoL1, and ApoM).”
Self-citationLipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2024) · Biochemical Journal · doi:10.1042/bcj20240037 · Cited by 59
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease
Doherty, S., Hernandez, S., Rikhi, R. R., Mirzai, S., Reyes, C. D. L., McIntosh, S. W., Block, R., & Shapiro, M. D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00760-1 · Cited by 62
“) [40].”
Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques
Erlinge, D., Tsimikas, S., Mæng, M., Maehara, A., Larsen, A. I., Engstrøm, T., Kjøller‐Hansen, L., Matsumura, M., Ben‐Yehuda, O., Bøtker, H. E., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.013 · Cited by 55
Current view: indications for extracorporeal lipid apheresis treatment
The German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Hulpke‐Wette, M., Hagenah, G. C., Schulz, E. G., & Wieland, E. (2012) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-012-0046-6 · Cited by 53
“Under actual consideration is an investigation, which identified LPA variants (LPA locus on 6q26–27) encoding Lp(a) lipoprotein that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease [33], but these results need further investigations to substantiate t…”
ResultLipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/563717 · Cited by 58
“In a prospective study [100], rs10455872 SNP was found associated with incident CHD, and in case-control studies [95, 101], a relationship between rs10455872 SNP and incident CHD and myocardial infarction was also observed.”
BackgroundLangsted, A., Varbo, A., Kamstrup, P. R., & Nordestgaard, B. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1096 · Cited by 53
Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study
Thomas, D. G., Wei, Y., & Tall, A. R. (2021) · Journal of Lipid Research · doi:10.1194/jlr.p120001000 · Cited by 49
Sahebkar, A., Serban, C., Ursoniu, S., & Banach, M. (2016) · Nutrition · doi:10.1016/j.nut.2015.06.009 · Cited by 52
“It has been shown that the size of unique protein apo(a) is genetically influenced by two common variants (rs10455872 and rs3798220) of the LPA gene [2,3].”
BackgroundGenome-wide association studies of late-onset cardiovascular disease
Smith, J. G., & Newton‐Cheh, C. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.04.004 · Cited by 56
“004 F in studies (termedMendelian Randomization studies)with results supportive of the causal link between coronary disease and higher blood pressure [68,69], higher plasma triglyceride level [70], higher plasma LDL cholesterol level [71], higher plasma lipoprotein(a) level [72], obesity [73], telomere length [74,75]…”
Romagnuolo, R., Scipione, C. A., Marcovina, S. M., Gemin, M., Seidah, N. G., Boffa, M. B., & Koschinsky, M. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180869 · Cited by 52
Inverse Association of Lipoprotein (a) With Markers of Insulin Resistance in Dyslipidemic Subjects
Vaverková, H., Karásek, D., Halenka, M., Cibičková, Ľ., & Kubíčková, V. (2017) · Physiological Research · doi:10.33549/physiolres.933583 · Cited by 54
“2009, Clarke et al. 2009) have been reported to be strongly associated with the risk of CVD. Surprisingly, recent studies found that serum Lp(a) concentrations are inversely associated with T2DM (Mora et al. 2010, Kamstrup and Nordestgaard 2013, Ye et al. 2014), pre-diabetes, insulin resistance and…”
BackgroundLipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study
Strandkjær, N., Hansen, M. K., Nielsen, S. T., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Nordestgaard, B. G., Tabor, A., Bundgaard, H., Iversen, K. K., & Kamstrup, P. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab734 · Cited by 57
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup, P. R., Neely, R. D. G., Nissen, S. E., Landmesser, U., Haghikia, A., Costa‐Scharplatz, M., Abbas, C. A., & Nordestgaard, B. G. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae032 · Cited by 54
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.